Association between the Cx371019 C &gt; T genetic variant and risk of breast cancer

Tabadkani, Mahla; Bani, Nastaran; Gharib, Masoumeh; Ziaeemehr, Aghigh; Samadi, Sara; Rastgar‐Moghadam, Azam; Mehramiz, Mehrane; Alavi, Negin; Moetamani‐Ahmadi, Mehrdad; Samadian, Mohammad; Vahaz, Fatemeh; Daghigh-Bazaz, Zohre-Sadat; Rajabian, Majid; Rahbarian, Raheleh; Ramshini, Hossein; Khazaei, Majid; Ferns, Gordon A.; Shaidsales, Soodabeh

doi:10.1016/j.mgene.2021.100925

Cited by 2 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the Cx37 319 residue is polymorphic in humans with either proline (Cx37-1019C) or serine (Cx37-1019T) residues present at high frequency within the general population [77][78][79][80][81]. The Cx37-1019C (Cx37-P319) variant -which presumably cannot be phosphorylated at the 319 site (but could be phosphorylated at nearby sites) -is strongly associated with increased risk for cardiovascular disease [78,80,81] and breast cancer [46]. Yet, in vitro studies in HeLa or SK-Hep-1 cancer cells find that Cx37-P319 -not Cx37-S319 -is growth suppressive [55].…”

Section: Phosphorylation Of Cx37 Likely Induces a Closed Channel Conf...mentioning

confidence: 99%

“…While in the postischemic hindlimb this was almost completely protective from ischemic tissue damage [7, 9], loss of Cx37 cannot be considered wholly beneficial. For example, Cx37 downregulation (via application of TNFα) exacerbates the risk of vascular malformation in mice with Smad1/5 haploinsufficiency [38] (a model of the rare genetic disease Hereditary Hemorrhagic Telangiectasia in which Alk1 signaling is dysregulated), and Cx37 polymorphism in humans is associated with increased risk for breast cancer [46], a highly vascularized cancer type [47], which may be due, at least in part, to more aggressive tumor angiogenesis. In humans, somatic mutations that impact the first transmembrane domain of Cx37 (and likely alter Cx37 gap junction channel function) have been linked to the development of hepatic hemangiomas, which are vascular malformations characterized by enlarged or excessive blood vessels [48, 49].…”

Section: Cx37 In the Vasculature Links Hemodynamic Flow To Endothelia...mentioning

confidence: 99%

See 1 more Smart Citation

Connexin37 Regulates Cell Cycle in the Vasculature

Fang

Burt

2022

J Vasc Res

View full text Add to dashboard Cite

Control of vascular cell growth responses is critical for development and maintenance of a healthy vasculature. Connexins – the proteins comprising gap junction channels – are key regulators of cell growth in diseases such as cancer, but their involvement in controlling cell growth in the vasculature is less well appreciated. Connexin37 (Cx37) is one of four connexin isotypes expressed in the vessel wall. Its primary role in blood vessels relies on its unique ability to transduce flow-sensitive signals into changes in cell cycle status of endothelial (and perhaps, mural) cells. Here, we review available evidence for Cx37’s role in the regulation of vascular growth, vessel organization, and vascular tone in healthy and diseased vasculature. We propose a novel mechanism whereby Cx37 accomplishes this with a phosphorylation-dependent transition between closed (growth-suppressive) and multiple open (growth-permissive) channel conformations that result from interactions of the C-terminus with cell-cycle regulators to limit or support cell cycle progression. Lastly, we discuss Cx37 and its downstream signaling as a novel potential target in the treatment of cardiovascular disease, and we address outstanding research questions that still challenge the development of such therapies.

show abstract

Section: Phosphorylation Of Cx37 Likely Induces a Closed Channel Conf...mentioning

confidence: 99%

Section: Cx37 In the Vasculature Links Hemodynamic Flow To Endothelia...mentioning

confidence: 99%

Connexin37 Regulates Cell Cycle in the Vasculature

Fang

Burt

2022

J Vasc Res

View full text Add to dashboard Cite

show abstract

“…The prognosis and therapy of this cancer depend on the type of cancer and its stage ( Waks and Winer, 2019 ). Primarily, breast cancer therapy includes medications, chemotherapy, radiation, and surgery to remove cancer cells from the human body ( DeSantis et al, 2019 ; Tabadkani et al, 2021 ). Because multiple agents are implicated at the beginning of cancer, these agents can show different signs depending on the kind and place of the tumor.…”

Section: Introductionmentioning

confidence: 99%

Application of MXene in the diagnosis and treatment of breast cancer: A critical overview

Ranjbari

Darroudi

Hatamluyi

et al. 2022

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

Breast cancer is the second most common cancer worldwide. Prognosis and timely treatment can reduce the illness or improve it. The use of nanomaterials leads to timely diagnosis and effective treatment. MXenes are a 2D material with a unique composition of attributes, containing significant electrical conductance, high optical characteristics, mechanical consistency, and excellent optical properties. Current advances and insights show that MXene is far more promising in biotechnology applications than current nanobiotechnology systems. MXenes have various applications in biotechnology and biomedicine, such as drug delivery/loading, biosensor, cancer treatment, and bioimaging programs due to their high surface area, excellent biocompatibility, and physicochemical properties. Surface modifications MXenes are not only biocompatible but also have multifunctional properties, such as aiming ligands for preferential agglomeration at the tumor sites for photothermal treatment. Studies have shown that these nanostructures, detection, and breast cancer therapy are more acceptable than present nanosystems in in vivo and in vitro. This review article aims to investigate the structure of MXene, its various synthesis methods, its application to cancer diagnosis, cytotoxicity, biodegradability, and cancer treatment by the photothermal process (in-vivo and in-vitro).

show abstract

Association between the Cx371019 C > T genetic variant and risk of breast cancer

Cited by 2 publications

References 37 publications

Connexin37 Regulates Cell Cycle in the Vasculature

Connexin37 Regulates Cell Cycle in the Vasculature

Application of MXene in the diagnosis and treatment of breast cancer: A critical overview

Contact Info

Product

Resources

About